



UK Sustainable Equity

Market context

Although the UK stock market lagged some other major developed equity markets in Q3, national equity benchmarks advanced amid broadly positive UK newsflow. The Bank of England (BoE) cut interest rates for the first time in four years, although Governor Andrew Bailey cautioned against a premature declaration of victory against inflation. Large-cap stocks generally lagged smaller companies, with the FTSE All-Share Index posting a stronger advance than the FTSE 100. However, consumer confidence fell in September in advance of October's budget, with the new government expected to lay out stringent measures to repair the public finances. At the sector level, consumer staples and utilities were the best parts of the UK equity market, with energy the notable loser on global growth concerns, which resulted in a 17% quarterly decline in the price of a barrel of Brent crude oil.

Performance

The Strategy delivered a positive return and outperformed the FTSE All-Share Index (in GBP, gross and net of fees)¹. At the sector level, stock selection in healthcare and financials made a notable contribution to relative returns, as did an underweight in energy. As a reminder, the UK Sustainable Equity strategy does not invest in the heavy extractive industries. Stock selection in industrials detracted.

At the stock level, the primary contributors to relative returns included Oxford Nanopore Technologies, which develops technologies used in DNA sequencing and drug development. It outperformed on an encouraging update that highlighted solid growth and improving cashflow metrics; the company also received an investment from Novo Holdings, which provides more financial support and has strengthened confidence in the business. Other contributors included WAG Payment Solutions, which offers a payment and mobility platform for commercial road transport; it outperformed on results that highlighted strong growth. National Grid was another outperformer, rising along with the utilities sector on expectations of interest-rate cuts; the conclusion of a rights issue and clear signs that the fundamentals of the business remain intact also supported the shares. Genus, an elite genetics company that helps improve the efficiency, environmental impact and quality of livestock herds, also contributed on good results, as well as more upbeat sentiment towards China, a major protein market. Finally for the contributors, not holding oil & gas majors BP and Shell benefited relative returns, given the weakness of the energy sector as oil prices fell.

The detractors from relative returns included pest control company Rentokil, which warned on growth in North America and profits, with the business facing ongoing challenges in integrating US acquisition Terminix. PureTech Health, a clinical-stage biotherapeutics company, was another detractor. Current market conditions present a challenge for PureTech Health, but the business continues to do the right things operationally. It has returned over £100m of cash to shareholders and several of its studies are nearing conclusions, which should lead to further commercial progress. Several industrial sector companies also detracted, on broad concerns about end-market demand due to inventory reductions and an uncertain outlook. They included Victrex, which creates high-performance polymer solutions with an industry focus on aerospace, energy and medical markets; Morgan Advanced Materials, which creates materials that help customers reduce energy consumption, emissions and operating costs, detracted; and Oxford Instruments, which

¹ Where performance is gross of fees, returns will be reduced by management fees and other expenses incurred. Net performance is net of highest institutional segregated portfolio management fee.

develops advanced instrumentation equipment for industry and scientific communities.

Portfolio activity

Buys

We added Spectris, a provider of test and measurement systems that help scientists and engineers monitor the environment, accelerate climate mitigation and adaptation, and build resilience. After five years of significant streamlining, the company is now focused on its strong competitive positions, which should lead to a stronger growth and returns profile in the future.

Top-ups included additional investments in Rentokil and Genus to take advantage of valuation opportunities following share-price weakness.

Sells

There were no full exits. We trimmed Ricardo and AJ Bell after strong performances.

Outlook

Even after a decent performance by UK equities in Q3, the UK market continues to trade at a material discount vs. history and global markets. This is reflected in the UK Sustainable Equity portfolio, where the current price-to-earnings ratio is lower than the historical average.

Since 2016, the UK market has had to navigate numerous headwinds: Brexit, COVID, the UK gilts crisis, high inflation and a succession of prime ministers. These events have created uncertainty that has weighed heavily on capital markets. Governing is never easy, as the early days of the new administration show, but we can hope that we have moved into a period of relative political stability. Combined with UK stocks offering good value and rebounding profits, this paints a favourable outlook for the UK market.

At the individual security level, we are excited by the fundamental progress we are seeing. We noted at the end of Q2 that recent data releases have shown operational progress in many of our holdings. Q3 saw more of the same, with encouraging updates from other companies in the portfolio, including Oxford Nanopore Technologies and WAG Payment Solutions, among others. We expect this to translate into further earnings growth later this year. And as earnings grow, we anticipate valuations will follow and ultimately align with the underlying fundamentals.

At this point in time, future earnings growth has still not been priced into the market. The current earnings-growth 'down-cycle' has been an extended one and, although matters have stabilised, there remains inventory uncertainty and caution over end-market demand, which is leading to some reticence on investment decisions and ordering patterns. However, we expect this to resolve in time, and continue to believe that the combination of attractive valuations and strong operational performance creates a significant opportunity for UK equity investors.

Specific risks.

Currency exchange: Changes in the relative values of different currencies may adversely affect the value of investments and any related income. Default: There is a risk that the issuers of fixed income investments (e.g. bonds) may not be able to meet interest payments nor repay the money they have borrowed. The worse the credit quality of the issuer, the greater the risk of default and therefore investment loss. Derivatives: The use of derivatives may increase overall risk by magnifying the effect of both gains and losses leading to large changes in value and potentially large financial loss. A counterparty to a derivative transaction may fail to meet its obligations which may also lead to a financial loss. Emerging market: These markets carry a higher risk of financial loss than more developed markets as they may have less developed legal, political, economic or other systems. Equity investment: The value of equities (e.g. shares) and equity-related investments may vary according to company profits and future prospects as well as more general market factors. In the event of a company default (e.g. insolvency), the owners of their equity rank last in terms of any financial payment from that company. Interest rate: The value of fixed income investments (e.g. bonds) tends to decrease when interest rates rise.

Important information

This communication is provided for general information only. Nothing herein should be construed as an offer to enter into any contract, investment advice, a recommendation of any kind, a solicitation of clients, or an offer, marketing or solicitation with respect to any particular strategy, security, derivative, services or investment product. The information may discuss general market activity or industry trends and is not intended to be relied upon as a forecast, research or investment advice. The economic and market views presented herein reflect Ninety One's judgment as at the date shown and are subject to change without notice. Views and opinions presented herein will be affected by changes in interest rates, general market conditions and other political, social and economic developments. There is no guarantee that views and opinions expressed will be correct and may not reflect those of Ninety One as a whole, different views may be expressed based on different investment objectives. Although we believe any information obtained from external sources to be reliable, we have not independently verified it, and we cannot guarantee its accuracy or completeness. Ninety One's internal data may not be audited. Ninety One does not provide legal or tax advice. Reliance upon information in this material is at the sole discretion of the reader. Investors should consult their own legal, tax and financial advisor prior to any investments. Past performance should not be taken as a guide to the future. Investment involves risks; losses may be made.

Any decision to invest in strategies described herein should be made after reviewing the offering document and conducting such investigation as an investor deems necessary and consulting its own legal, accounting and tax advisors in order to make an independent determination of suitability and consequences of such an investment. This material does not purport to be a complete summary of all the risks associated with this Strategy. A description of risks associated with this Strategy can be found in the offering or other disclosure documents. Copies of such documents are available free of charge upon request.

This is not a buy, sell or hold recommendation for any particular security. Individual security performance does not represent the Strategy performance. There is no guarantee that the Strategy is currently investing and/or will invest in the securities in the future. The portfolio may change significantly over a short period of time. Forecasts are inherently limited and are not a reliable indicator of future performance.

In the US, this communication should only be read by institutional investors, professional financial advisers and their eligible clients, but must not be distributed to US persons apart from the aforementioned recipients. In Australia, this document is provided for general information only to wholesale clients (as defined in the Corporations Act 2001). For Funds within the Strategy that are registered for sale in Switzerland, copies of the Prospectus, latest annual and semi-annual Report & Accounts, Articles of Incorporation and Key Investor Information Documents may be obtained from the Swiss Representative and Paying Agent, RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich, Switzerland.

For distribution into Asia, this material should only be sent to professional investors, institutional investors and other qualified investors as defined by relevant local laws and regulations, and not to be distributed to the public or within a country where such distribution would be contrary to applicable law or regulations. It is strictly for the recipient's use only and should not be reproduced or distributed to any other persons without prior written consent from Ninety One. If you are not an intended recipient you must ignore this material and take no action based on the information in it. In Hong Kong, it is for professional investors only, issued by Ninety One Hong Kong Limited and has not been reviewed by the Securities and Futures Commission (SFC). In Singapore, it is for institutional investors only, issued by Ninety One Singapore Pte Limited (company registration number: 201220398M) and has not been reviewed by the Monetary Authority of Singapore. In the People's Republic of China (the "PRC"), it can be directed only at certain eligible PRC investors as prescribed by applicable PRC laws. In Taiwan, it is for professional institutional investors only. In Indonesia, Thailand, the Philippines and Brunei, it is for institutional investors and other qualified investors only. This material has been issued to you upon your request, without any marketing or solicitation activities conducted by Ninety One.

Except as otherwise authorised, this information may not be shown, copied, transmitted, or otherwise given to any third party without Ninety One's prior written consent. © 2024 Ninety One. All rights reserved. Issued by Ninety One.